Norris Perne & French’s Opus Genetics IRD Stock Holding History

Norris Perne & French’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-78,909	Closed	-$417K	–	147
2021 Q2	$417K	Hold	78,909	–	–	0.04%	100
2021 Q1	$458K	Buy	+78,909	New	+$733K	0.04%	92

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Norris Perne & French's IRD Position: Q3 2021 in Review

Norris Perne & French sold out of Opus Genetics (IRD) in Q3 2021, closing a stake of 78,909 shares — an estimated $417K sold.

Norris Perne & French first reported a position in IRD in Q1 2021 and held it in 2 quarters. The position peaked at $458K in Q1 2021. 30 funds tracked by Wall St. Rank hold IRD as of Q3 2021.

Norris Perne & French reported no remaining Opus Genetics position as of Q3 2021 after selling out during the quarter.
Norris Perne & French sold 78,909 Opus Genetics shares in Q3 2021, an estimated $417K.
Norris Perne & French first reported a position in Opus Genetics in Q1 2021 and held it in 2 quarters.
Norris Perne & French's Opus Genetics position peaked at $458K in Q1 2021.
30 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2021.

Based on Norris Perne & French's 13F filing for Q3 2021, filed 26 Oct 2021.